On December 22, 2025, the FDA approved oral Wegovy (semaglutide), the first-ever pill formulation of a GLP-1 therapy for obesity and cardiovascular risk reduction. Novo Nordisk, the manufacturer of Wegovy, plans to launch the oral product in January 2026, signaling a major shift in the weight-loss drug landscape.
While previously, GLP-1s for weight loss all required regular injections, oral Wegovy is now significantly more accessible to individuals who may have previously avoided injectables. Clinical trials show oral Wegovy delivers comparable efficacy to injectable formulations, with average weight loss of 16.6%, though gastrointestinal side effects (nausea, vomiting, diarrhea) were more frequent.
Adding to the momentum of oral GLP-1 drugs, Eli Lilly’s oral GLP-1 candidate, orforglipron, is currently under FDA priority review and could launch later in 2026. Unlike oral semaglutide, orforglipron has no food restrictions and demonstrated strong weight maintenance in trials, positioning it as a competitive alternative.
Potential Impact of Oral GLP-1s
The introduction of oral GLP-1s will likely expand demand for GLP-1s further, creating new considerations and challenges for employer-sponsored plans.
- Cost Pressure: Even if unit prices decline from current levels, broader adoption of GLP-1s could increase total spend. Long-term use of GLP-1s is often required to maintain any weight loss over time, amplifying the potential budget impact.
- Formulary Complexity: Employers must decide whether oral GLP-1s will be treated as lifestyle drugs or chronic-disease interventions. These therapies are now FDA approved for multiple non-weight loss indications. Coverage decisions will influence utilization and member expectations.
- Utilization Management: Prior authorization, BMI thresholds, and step therapy will remain important avenues to manage access and cost. Oral formulations may require establishing new or updated criteria to address adherence and side-effect profiles.
What Employers Can Do Now
Engage PBMs and Benefits Consultants Early
Speak with your PBM vendor and ask how oral GLP-1s will be integrated into formularies, including whether tiering or rebate structures should be expected to change.
Model Potential Cost Scenarios
Estimate potential utilization shifts if the reduced barriers to entry significantly increase interest from members. Consider both short-term pricing and long-term adherence trends.
Review Coverage Criteria
Align eligibility rules with your plan philosophy, whether it is more focused on chronic disease prevention or weight management.
Monitor Market Signals
Watch for updated GLP-1 pricing, expecting potential formulary adjustments as PBMs respond to new oral options.
Looking Ahead
Employers should prepare for significant changes as oral GLP-1 therapies enter the market. Removing the injection requirement for taking GLP-1s will likely drive higher demand, creating new utilization and cost pressures even if per-unit pricing declines. Looking ahead, Lilly’s orforglipron may also further disrupt coverage dynamics. Acting now by engaging PBMs, modeling cost scenarios, and preparing member communications will help employers mitigate their plan’s financial risks and manage member expectations as this category grows.
Truveris will be monitoring updates around pricing and Eli Lilly’s drug launch, and will continue sharing more as additional information emerges.
Truveris is a pharmacy cost containment company dedicated to reducing pharmacy costs and driving transparency for employers and benefit consultants. Our proprietary, data-driven technology and deep industry expertise empower smarter pharmacy benefit decisions through contract optimization and PBM oversight. Independent and unbiased, Truveris delivers measurable savings and accountability across every pharmacy program.
